CSIMarket


Sonoma Pharmaceuticals Inc   (SNOA)
Other Ticker:  
 

Sonoma Pharmaceuticals Inc

SNOA's Fundamental analysis








Looking into Sonoma Pharmaceuticals Inc growth rates, revenue grew by 6.59 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 317

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -4.89 %

Sonoma Pharmaceuticals Inc net loss deacreased by in III. Quarter 2023 year on year, Sonoma Pharmaceuticals Inc net loss increased by -55.34 % in III. Quarter 2023 year on year,

More on SNOA's Growth


Sonoma Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Sonoma Pharmaceuticals Inc PEG ratio is at -0
Company
PE TTM   
Industry
-
PE TTM    
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.32.


More on SNOA's Valuation
 
 Total Debt (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 4.87
 Tangible Book Value (Per Share $)

Sonoma Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Sonoma Pharmaceuticals Inc PEG ratio is at -0
Company
PE TTM   
Industry
-
PE TTM    
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.32.